Pharma major Cipla Ltd has been up 12 percent this week, up 14 percent this month, and up 70 percent for the year. On Friday, the stock made a fresh 52-week high and a fresh lifetime high as well. It is a stock which is correcting 2-2.5 years of underperformance.
The move is on the back of Irish pharma company Perrigo voluntarily recalling its inhaler. Analysts are now building in $60 million in sales for the company. However, the big question is how much of that gets priced in. CNBC-TV18’s Anuj Singhal in the special segment Stock 360 gets a detailed view on the stock.To watch other videos in this series, click the Stock 360 tab below.